A randomised, double-blind, placebo-controlled, two-way crossover study, to evaluate the effect of a single oral dose of BNC210 on CCK-4 induced panic-like symptoms in healthy young male subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2011
At a glance
- Drugs BNC 210 (Primary)
- Indications Anxiety disorders; Panic symptoms
- Focus Pharmacodynamics
- 15 Nov 2011 Results were reported at the 41st Annual Meeting of the Society for Neuroscience, according to a Bionomics media release.
- 30 Mar 2011 Primary endpoint 'Symptom-rate' has been met.
- 30 Mar 2011 Positive preliminary results have been reported in a Bionomics media release; the company anticipates that data from this trial will be presented at a major scientific conference later this year.